Milestone Pharmaceuticals Receivables 2018-2024 | MIST

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Milestone Pharmaceuticals receivables from 2018 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Milestone Pharmaceuticals receivables from 2018 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.3B
Vertex Pharmaceuticals (VRTX)	$122B
Bristol Myers Squibb (BMY)	$112.5B
Gilead Sciences (GILD)	$111.9B
Regeneron Pharmaceuticals (REGN)	$91.4B
CSL (CSLLY)	$90.8B
GSK (GSK)	$76.6B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$34.8B
BioNTech SE (BNTX)	$25.9B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.5B
Moderna (MRNA)	$20.6B
BeiGene (BGNE)	$20.2B
Genmab (GMAB)	$15.1B
Incyte (INCY)	$14.6B
Exact Sciences (EXAS)	$13.1B
BioMarin Pharmaceutical (BMRN)	$12.6B
Insmed (INSM)	$12.2B
Bio-Techne Corp (TECH)	$12B
Vaxcyte (PCVX)	$11.9B
Sarepta Therapeutics (SRPT)	$11.7B
QIAGEN (QGEN)	$10B
Exelixis (EXEL)	$9.8B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.5B
Legend Biotech (LEGN)	$8B
Repligen (RGEN)	$7.8B